Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Herbrecht

Showing results (1-10 of 136) with videos related to

Pageof 14
Sort By:
Presse Medicale (Paris, France : 1983)|October 10, 1998
[Management of febrile episodes in neutropenic patients]R Herbrecht
European Journal of Haematology. Supplementum|January 1, 1996
The changing epidemiology of fungal infections: are the lipid-forms of amphotericin B an advance?R Herbrecht
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|January 1, 1997
Safety of amphotericin B colloidal dispersionR Herbrecht
Annals of Hematology|March 4, 2003
Improving the outcome of invasive aspergillosis: new diagnostic tools and new therapeutic strategiesR Herbrecht
International Journal of Clinical Practice|August 18, 2004
Posaconazole: a potent, extended-spectrum triazole anti-fungal for the treatment of serious fungal infectionsR Herbrecht
The Journal of Antimicrobial Chemotherapy|July 1, 1997
Safety and efficacy of Intralipid emulsions of amphotericin BR Herbrecht, V Letscher
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|June 18, 1998
Prospective study of bacteraemia in cancer patients. Results of a French multicentre studyM C Escande, R Herbrecht
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 1, 1995
The safety and efficacy of amphotericin B colloidal dispersion in the treatment of invasive mycosesB A Oppenheim, R Herbrecht, S Kusne
Transplant Infectious Disease : an Official Journal of the Transplantation Society|June 29, 2001
Amphotericin B and its new formulations: pharmacologic characteristics, clinical efficacy, and tolerabilityM Tiphine, V Letscher-Bru, R Herbrecht
La Revue Du Praticien|June 5, 2001
[Visceral candidiasis]R Herbrecht, A Zamfir, V Letscher-Bru
Pageof 14

Showing results (1-10 of 136) with videos related to

Sort By:
Pageof 14
Presse Medicale (Paris, France : 1983)|October 10, 1998
[Management of febrile episodes in neutropenic patients]R Herbrecht
European Journal of Haematology. Supplementum|January 1, 1996
The changing epidemiology of fungal infections: are the lipid-forms of amphotericin B an advance?R Herbrecht
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|January 1, 1997
Safety of amphotericin B colloidal dispersionR Herbrecht
Annals of Hematology|March 4, 2003
Improving the outcome of invasive aspergillosis: new diagnostic tools and new therapeutic strategiesR Herbrecht
International Journal of Clinical Practice|August 18, 2004
Posaconazole: a potent, extended-spectrum triazole anti-fungal for the treatment of serious fungal infectionsR Herbrecht
The Journal of Antimicrobial Chemotherapy|July 1, 1997
Safety and efficacy of Intralipid emulsions of amphotericin BR Herbrecht, V Letscher
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|June 18, 1998
Prospective study of bacteraemia in cancer patients. Results of a French multicentre studyM C Escande, R Herbrecht
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 1, 1995
The safety and efficacy of amphotericin B colloidal dispersion in the treatment of invasive mycosesB A Oppenheim, R Herbrecht, S Kusne
Transplant Infectious Disease : an Official Journal of the Transplantation Society|June 29, 2001
Amphotericin B and its new formulations: pharmacologic characteristics, clinical efficacy, and tolerabilityM Tiphine, V Letscher-Bru, R Herbrecht
La Revue Du Praticien|June 5, 2001
[Visceral candidiasis]R Herbrecht, A Zamfir, V Letscher-Bru
Pageof 14